Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Homidium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 7/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 5/20 | 0.97 |
| ▸ | BLM | P54132 | 4/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.97 |
| ▸ | HPGD | P15428 | 4/20 | 0.97 |
| ▸ | HTT | P42858 | 4/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | THRB | P10828 | 3/20 | 0.97 |
| ▸ | CASP1 | P29466 | 3/20 | 0.97 |
| ▸ | RECQL | P46063 | 3/20 | 0.97 |
| ▸ | CASP7 | P55210 | 3/20 | 0.97 |
| ▸ | TERT | O14746 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.97 |
| ▸ | MITF | O75030 | 2/20 | 0.97 |
| ▸ | NSD2 | O96028 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Homidium SCHEMBL21647365 | 0.99 | MEN1 (1.00) | MEN1KMT2AMAPTBLMKDM4E | |
| Homidium SCHEMBL31511751 | 0.99 | MEN1 (1.00) | MEN1KMT2AMAPTBLMKDM4E | |
| Homidium SCHEMBL29391335 | 0.99 | MEN1 (1.00) | MEN1KMT2AMAPTBLMKDM4E | |
| Homidium SCHEMBL27609 | 0.99 | MEN1 (1.00) | MEN1KMT2AMAPTBLMKDM4E | |
| Homidium SCHEMBL7521343 | 0.97 | MEN1 (0.95) | MEN1KMT2AMAPTBLMKDM4E | |
| Homidium SCHEMBL19690770 | 0.97 | MEN1 (0.97) | MEN1KMT2AMAPTBLMKDM4E | |
| Homidium SCHEMBL3025214 | 0.97 | MEN1 (1.00) | MEN1KMT2AMAPTBLMKDM4E | |
| Homidium SCHEMBL11023665 | 0.97 | MEN1 (0.97) | MEN1KMT2AMAPTBLMKDM4E | |
| Homidium SCHEMBL7751164 | 0.97 | MEN1 (1.00) | MEN1KMT2AMAPTBLMKDM4E | |
| Homidium SCHEMBL20520 | 0.97 | MEN1 (1.00) | MEN1KMT2AMAPTBLMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113042216-B | Flotation separation method for carbonaceous lead sulfide zinc minerals | 中南大学 | 2022-06-03 | — | — | CN | claimed |
| CN-114011584-A | Preparation method and application of copper-arsenic flotation separation inhibitor for mixed copper ore | 广西大学 | 2022-02-08 | — | — | CN | claimed |
| CN-113926594-A | Lead-zinc ore flotation method | 深圳市中金岭南有色金属股份有限公司凡口铅锌矿 | 2022-01-14 | — | — | CN | claimed |
| CN-108697091-B | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 美国陶氏益农公司 | 2021-07-23 | — | — | CN | claimed |
| CN-113042216-A | Flotation separation method for carbonaceous lead sulfide zinc minerals | 中南大学 | 2021-06-29 | — | — | CN | claimed |
| CN-113019711-A | Comprehensive utilization method for separating high-zinc jamesonite concentrate | 昆明理工大学 | 2021-06-25 | — | — | CN | claimed |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | claimed |
| EP-3464312-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | claimed |
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | claimed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | claimed |
| WO-2017210408-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | claimed |
| WO-2004092739-A1 | METHOD FOR MASS SPECTROMETRY INVOLVING FLUORESCENT LABELING OF THE ANALYTE | AMERSHAM BIOSCIENCES K.K. (JP) | 2004-10-28 | — | — | WO | claimed |
| US-5001051-A | Dose critical in-vivo detection of anti-cancer drug levels in blood | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-03-19 | — | — | US | claimed |
| CN-118355022-A | Nucleoside analogues for the treatment of parasitic infections | 安特卫普大学 | 2024-07-16 | — | — | CN | disclosed |
| CN-113182081-B | Flotation reagent and method for flotation separation of bismuth-zinc-sulfur polymetallic sulfide ore | 赣州有色冶金研究所有限公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-115445776-A | Separation method applied to copper-lead bulk concentrates | 昆明理工大学 | 2022-12-09 | — | — | CN | disclosed |
| US-4468462-A | Vectors for cloning in streptomyces | ELI LILLY AND COMPANY (US) | 1984-08-28 | — | — | US | disclosed |
| EP-0115173-A2 | Cloning vectors in streptomyces | ELI LILLY AND COMPANY (US) | 1984-08-08 | — | — | EP | disclosed |
| US-4416994-A | SENSITIZATION OF ANTIBIOTIC RESISTANT DNA SEGMENTS BY PAIRING | ELI LILLY AND COMPANY (US) | 1983-11-22 | — | — | US | disclosed |
| EP-0077650-A2 | Cloning vectors | ELI LILLY AND COMPANY (US) | 1983-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280399-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | ACHE 3647/4885MEN1 1965/4885KMT2A 1818/4885 |
| US-10420772-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | ACHE 3647/4885MEN1 1965/4885KMT2A 1818/4885 |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | ACHE 3647/4885MEN1 1965/4885KMT2A 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.